SEC Form 8-K Summary
Registrant: Tivic Health Systems, Inc. (the request metadata identifies Valion Bio, Inc.; the filing itself identifies Tivic Health Systems, Inc.)
Reporting date: October 17, 2022. The filing was submitted under Item 7.01, Regulation FD Disclosure, and Item 9.01(d), Exhibits.
Business Context and Reporting Period
Tivic Health announced that it executed a purchase agreement to acquire substantially all of the assets of Reliefband Technologies, LLC. The company also began using a new corporate presentation dated October 2022.
The filing does not provide a quarterly or annual financial reporting period and does not include financial statements.
Financial Metrics and Capitalization
- Revenue, net income, operating cash flow, margins, debt, liquidity, and other financial metrics are not provided in the filing text.
- Purchase consideration, financing terms, closing conditions, and expected financial impact of the Reliefband asset acquisition are not stated in the filing text provided.
- Tivic Health’s common stock trades on Nasdaq under the symbol TIVC.
Material Changes and Unusual Items
- Execution of an agreement to acquire substantially all assets of Reliefband Technologies, LLC is the principal disclosed corporate transaction.
- The filing announces a new corporate presentation and provides it as Exhibit 99.2.
- The press release and corporate presentation were furnished, rather than filed, under Item 7.01 and generally are not subject to Section 18 liability or incorporated by reference into other filings unless specifically referenced.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or quantified outlook information. It includes customary forward-looking statement disclosures, warning that actual results may differ materially because of known and unknown risks, uncertainties, and other factors. The filing text does not identify detailed transaction-specific risks or contingencies.
Key Facts to Verify
- Review Exhibit 99.1 for the purchase price, assets acquired, transaction structure, closing conditions, and expected timing.
- Review Exhibit 99.2 for management’s business strategy, market opportunity, product information, and any projections or non-GAAP measures.
- Confirm whether the Reliefband transaction closed and assess its effect on revenue, expenses, cash needs, and liquidity in subsequent filings.
- Reconcile the filing’s registrant, Tivic Health Systems, Inc., with the request metadata identifying Valion Bio, Inc.